A Review of Corneal Melting after Boston Keratoprosthesis

References

• Dunlap K, Chak G, Aquavella JV, et al. Short-term visual outcomes of Boston type 1 keratoprosthesis implantation. Ophthalmology 2010;117(4):687–692
   PubMed Web of Science ®Google Scholar
• Robert M, Harissi-Dagher M. Boston type 1 keratoprosthesis: the CHUM experience. Can J Ophthalmol 2011;46(2):164–168
   PubMed Web of Science ®Google Scholar
• Chew HF, Ayres BD, Hammersmith KM, et al. Boston keratoprosthesis outcomes and complications. Cornea 2009;28:989–996
   PubMed Web of Science ®Google Scholar
• Shihadeh W, Mohidat H. Outcomes of the Boston keratoprosthesis in Jordan. Middle East Afr J Ophthalmol 2012;19(1):97–100
   PubMedGoogle Scholar
• Aldave AJ, Sangwan VS, Basu S, et al. International results with the Boston type 1 keratoprosthesis. Ophthalmology 2012;119(8):1530–1538
   PubMed Web of Science ®Google Scholar
• Patel A, Wu E, Ritterband D, Seedor J. Boston type 1 keratoprosthesis: the New York Eye and Ear experience. Eye 2012;26(3):418–425
   PubMed Web of Science ®Google Scholar
• de la Paz M, Stoiber J, de Rezende Couto Nascimento V, et al. Anatomical survival and visual prognosis of Boston type 1 keratoprosthesis in challenging cases. Graefes Arch Clin Exp Ophthalmol 2014;252(1):83–90
   PubMed Web of Science ®Google Scholar
• Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 2011;118(8):1543–1550
   PubMed Web of Science ®Google Scholar
• Ciolino JB, Belin M, Todani A, et al. Retention of the Boston keratoprosthesis type 1: multicenter study results. Ophthalmology 2013;120(6):1195–1200
   PubMed Web of Science ®Google Scholar
• Utine CA, Tzu JH, Akpek EK. Clinical features and prognosis of Boston type 1 keratoprosthesis-associated corneal melt. Ocul Immunol Inflamm 2011;19(6):413–418
   PubMed Web of Science ®Google Scholar
• Fini ME, Cook JR, Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res 1998;290:S12–23
   PubMed Web of Science ®Google Scholar
• Gross J. How tadpoles lose their tails: path to discovery of the first matrix metalloproteinase. Matrix Biol 2004;23(1):3–13
   PubMed Web of Science ®Google Scholar
• Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013;13(9):649–665
   PubMed Web of Science ®Google Scholar
• Brown DM, Chwa M, Escobar M, Kenney M. Characterization of the major matrix degrading metalloproteinase of human corneal stroma: evidence for an enzyme/inhibitor complex. Exp Eye Res 1991;52(1):5–16
   PubMed Web of Science ®Google Scholar
• Girard M, Matsubara M, Kublin C, et al. Stromal fibroblast synthesize collagenase and stromelysin during long-term tissue remodeling. J Cell Sci 1993;104(4):1001–1011
   PubMedGoogle Scholar
• Matsubara M, Girard M, Kublin C, et al. Differential roles for the two gelatinolytic enzymes of the matrix metalloproteinase family. Dev Biol 1991;147(2):425–439
   PubMed Web of Science ®Google Scholar
• Li D-Q, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001;73(4):449–459
   PubMed Web of Science ®Google Scholar
• Kim H-S, Shang T, Chen Z, et al. TGF-β1 stimulates production of gelatinase (MMP-9), collagenases (MMP-1, -13) and stromelysins (MMP-3, -10, -11) by human corneal epithelial cells. Exp Eye Res 2004;79(2):263–274
   PubMed Web of Science ®Google Scholar
• Maeda H, Okamoto T, Akaike T. Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals. Biol Chem 1998;379(2):193–200
   PubMed Web of Science ®Google Scholar
• Baker A, Edwards D, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;1(115):3719–3727
   Google Scholar
• Fini M, Parks W, Rinehart W, et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathology 1996;149(4):1287–1302
   PubMed Web of Science ®Google Scholar
• Smith V, Rishmawi H, Hussein H, Easty D. Tear film MMP accumulation and corneal disease. Br J Ophthalmol 2001;85(2):147–153
   PubMed Web of Science ®Google Scholar
• Smith V, Hoh H, Easty D. Role of ocular matrix metalloproteinases in peripheral ulcerative keratitis. Br J Ophthalmol 1999;83(12):1376–1383
   PubMed Web of Science ®Google Scholar
• O'Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001;108(4):656–659
   PubMed Web of Science ®Google Scholar
• Slansky H, Gnädinger M, Itoi M, Dohlman C. Collagenase in corneal ulcerations. Arch Ophthalmol 1969;82(1):108–111
   PubMedGoogle Scholar
• Dudenhoefer EJ, Nouri M, Gipson IK, et al. Histopathology of explanted collar button keratoprostheses: a clinicopathologic correlation. Cornea 2003;22(5):424–428
   PubMed Web of Science ®Google Scholar
• Coassin M, Zhang C, Green W, et al. Histopathologic and immunologic aspects of alphacor artificial corneal failure. Am J Ophthalmol 2007;144(5):699–704
   PubMed Web of Science ®Google Scholar
• Riley M. Glucose and oxygen utilization by the rabbit cornea. Exp Eye Res 1969;8(2):193–200
   PubMed Web of Science ®Google Scholar
• Turss R, Friend J, Dohlman C. Effect of a corneal fluid barrier on the nutrition of the epithelium. Exp Eye Res 1970;9(2):254–259
   PubMed Web of Science ®Google Scholar
• Thoft R, Friend J, Dohlman C. Corneal glucose flux. II. Its response to anterior chamber blockage and endothelial damage. Arch Ophthalmol 1971;86(6):685–691
   PubMedGoogle Scholar
• Bourges J, Trong T, Ellies P, et al. Intrastromal corneal ring segments and corneal anterior stromal necrosis. J Cataract Refract Surg 2003;29(6):1228–1230
   PubMed Web of Science ®Google Scholar
• Harissi-Dagher M, Khan BF, Schaumberg DA, Dohlman CH. Importance of nutrition to corneal grafts when used as a carrier of the Boston keratoprosthesis. Cornea 2007;26(5):564–568
   PubMed Web of Science ®Google Scholar
• Sivaraman KR, Hou JH, Allemann N, et al. Retroprosthetic membrane and risk of sterile keratolysis in patients with type 1 Boston keratoprosthesis. Am J Ophthalmol 2013;155(5):814–822
   PubMed Web of Science ®Google Scholar
• Stacy R, Jakobiec F, Michaud N, et al. Characterization of retrokeratoprosthetic membranes in the Boston type 1 keratoprosthesis. Arch Ophthalmol 2011;129(3):310–316
   PubMedGoogle Scholar
• Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea 2001;20(1):19–23
   PubMed Web of Science ®Google Scholar
• Arafat S, Suelves A, Spurr-Michaud S, et al. Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with Stevens-Johnson syndrome and ocular cicatricial pemphigoid. Ophthalmology 2014;121(1):79–87
   PubMed Web of Science ®Google Scholar
• Sayegh RR, Ang LPK, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson Syndrome. Am J Ophthalmol 2008;145(3):438–444
   PubMed Web of Science ®Google Scholar
• Chan CC, Holland EJ. Infectious keratitis after Boston type 1 keratoprosthesis implantation. Cornea 2012;31(10):1128–1134
   PubMed Web of Science ®Google Scholar
• Kim M, Yu F, Aldave A. Microbial keratitis after Boston type I keratoprosthesis implantation: incidence, organisms, risk factors, and outcomes. Ophthalmology 2013;120(11):2209–2216
   PubMed Web of Science ®Google Scholar
• Corrales R, Stern M, De Paiva C, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci 2006;47(8):3293–3302
   PubMed Web of Science ®Google Scholar
• Li D, Chen Z, Song X, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004;45(12):4302–4301
   PubMed Web of Science ®Google Scholar
• Dohlman C, Dudenhoefer E, Khan B, Morneault S. Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses. CLAO 2002;28(2):72–74
   PubMedGoogle Scholar
• Harissi-Dagher M, Beyer J, Dohlman CH. The role of soft contact lenses as an adjunct to the Boston keratoprosthesis. Int Ophthalmol Clin 2008;48(2):43–51
   PubMedGoogle Scholar
• Balasubramanian S, Pye D, Willcox M. Effects of eye rubbing on the levels of protease, protease activity and cytokines in tears: relevance in keratoconus. Clin Exp Optom 2013;96(2):214–218
   PubMed Web of Science ®Google Scholar
• Purdue P, Koulouvaris P, Nestor B, Sculco T. The central role of wear debris in periprosthetic osteolysis. HSS J 2006;2(2):102–113
   PubMedGoogle Scholar
• Syggelos S, Aletras A, Smirlaki I, Skandalis S. Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome. Biomed Res Int 2013. doi: 10.1155/2013/230805
   PubMed Web of Science ®Google Scholar
• Sharma C, Velpandian T, Baskar S, et al. Effect of fluoroquinolones on the expression of matrix metalloproetinase in debrided cornea of rats. Toxicol Mech Methods 2011;21(1):6–12
   PubMed Web of Science ®Google Scholar
• Schachtschabel U, Lindsey J, Weinreb R. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000;11(2):112–115
   PubMedGoogle Scholar
• Reviglio V, Rana T, Li Q, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg 2003;29(5):989–997
   PubMed Web of Science ®Google Scholar
• Phillips K, Arffa R, Cintron C, et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983;101(4):640–643
   PubMedGoogle Scholar
• Utine C, Tzu J, Akpek E. Clinical features and prognosis of Boston type 1 keratoprosthesis-associated corneal melt. Ocul Immunol Inflamm 2011;19(6):413–418
   PubMed Web of Science ®Google Scholar
• Najem K, Sebag M, Harissi-Dagher M. Boston keratoprosthesis type 1 device leak. Can J Ophthalmol 2014;49(1):106–108
   PubMed Web of Science ®Google Scholar
• Shapiro BL, Cortés DE, Chin EK, et al. High-resolution spectral domain anterior segment optical coherence tomography in type 1 Boston keratoprosthesis. Cornea 2013;32(7):951–955
   PubMed Web of Science ®Google Scholar
• Fernandez A, Radcliffe N, Sippel K, et al. Boston type I keratoprosthesis-donor cornea interface evaluated by high-definition spectral-domain anterior segment optical coherence tomography. Clin Ophthalmol 2012;6:1355–1359
   PubMedGoogle Scholar
• Zhou H, Kimura K, Orita T, et al. Inhibition by medroxyprogesterone acetate of interleukin-1β-induced collagen degradation by corneal fibroblasts. Invest Ophthalmol Vis Sci 2012;28(53):7
   Google Scholar
• Fitton J, Ziegelaar B, Hicks C, et al. Assessment of anticollagenase treatments after insertion of a keratoprosthetic material in the rabbit cornea. Cornea 1998;17(1):108–114
   PubMed Web of Science ®Google Scholar
• Newsome N, Gross J. Prevention by medroxyprogesterone of perforation in the alkali-burned rabbit cornea: inhibition of collagenolytic activity. Invest Ophthalmol Vis Sci 1977;16(1):21–31
   PubMed Web of Science ®Google Scholar
• Lass J, Campbell R, Rose J, et al. Medroxyprogesterone on corneal ulceration: its effects after alkali burns on rabbits. Arch Ophthalmol 1981;99(4):673–676
   PubMedGoogle Scholar
• Lass J, Berman M, Campbell R, et al. Treatment of experimental herpetic interstitial keratitis with medroxyprogesterone. Arch Ophthalmol 1980;98(3):520–527
   PubMedGoogle Scholar
• Dohlman C. Postoperative regimen and repair of complications after keratoprosthesis surgery. Refract Corneal Surg 1993;9:198
   Google Scholar
• Hicks CR, Crawford GJ. Melting after keratoprosthesis implantation: the effects of medroxyprogesterone. Cornea 2003;22(6):497–500
   PubMed Web of Science ®Google Scholar
• Dohlman J, Foster C, Dohlman CH. Boston keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis. Digit J Ophthalmol 2009;15(1). Available from: http://www.djo.harvard.edu/site.php?url=/physicians/oa/1319
   Google Scholar
• Dohlman C, Dudenhoefer E, Khan B, Dohlman J. Corneal blindness from end-stage Sjögren's syndrome and graft-versus-host disease. In: Sullivan D, Stern M, Tsubota K, et al. (eds.), Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3; pp. 1335–1338. New York: Kluwer/Plenum Publishers, 2002
   Google Scholar
• Antao S, Ayoub T, Tahir H, Parmar D. Stabilization of bilateral progressive rheumatoid corneal melt with infliximab. Case Rep Ophthalmol Med 2012;173793:1–3
   Google Scholar
• Pham M, Chow CC, Badawi D, Tu EY. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn Disease. Am J Ophthalmol 2011;152(2):183–188
   PubMed Web of Science ®Google Scholar
• Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea 2005;24(6):742–744
   PubMed Web of Science ®Google Scholar
• Odorcic S, Keystone EC, Ma JJK. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Cornea 2009;28(1):89–92
   PubMed Web of Science ®Google Scholar
• Durand ML, Dohlman CH. Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea 2009;28(8):896–901
   PubMed Web of Science ®Google Scholar
• Todani A, Ciolino JB, Ament JD, et al. Titanium back plate for a PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin Exp Ophthalmol 2011;249(10):1515–1518
   PubMed Web of Science ®Google Scholar
• Cruzat A, Shukla A, Dohlman C, Colby K. Wound anatomy after type 1 Boston KPro using oversized back plates. Cornea 2013;32(12):1532–1536
   Web of Science ®Google Scholar
• Rudnisky CJ, Belin MW, Todani A, et al. Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1. Ophthalmology 2012;119(5):1–5
   PubMed Web of Science ®Google Scholar
• Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type 1 keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 2009;116(4):640–651
   PubMed Web of Science ®Google Scholar
• Bradley JC, Hernandez EG, Schwab IR, Mannis MJ. Boston type 1 keratoprosthesis: the University of California Davis experience. Cornea 2009;28(3):321–327
   PubMed Web of Science ®Google Scholar
• Muñoz-Gutierrez G, Alvarez de Toledo J, Barraquer R, et al. Post-surgical visual outcome and complications in Boston type 1 keratoprosthesis. Arch Soc Esp Oftalmol 2013;88(2):56–68
   PubMedGoogle Scholar